Last update 01 Nov 2024

LIV-1 x Tubulin

Basic Info

Related Targets
LIV-1Tubulin

Related

1
Drugs associated with LIV-1 x Tubulin
Ladiratuzumab vedotin
Target
LIV-1 x Tubulin
Mechanism
LIV-1 inhibitors [+1]
Active Org.-
Originator Org.
Seagen Inc.Seagen Inc.
Active Indication-
Inactive Indication
Advanced Malignant Solid Neoplasm [+10]
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
6
Clinical Trials associated with LIV-1 x Tubulin
EUCTR2019-001946-17-IT / Not yet recruitingPhase 2
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors - Phase 2 Study of LV in Advanced Solid Tumors
NCT04032704 / TerminatedPhase 2
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
100 Clinical Results associated with LIV-1 x Tubulin
Login to view more data
100 Translational Medicine associated with LIV-1 x Tubulin
Login to view more data
0 Patents (Medical) associated with LIV-1 x Tubulin
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free